Search
News & Events
Urgent action needed to stop 500 preventable deathsA new report predicts rheumatic heart disease (RHD) will lead to over 500 preventable deaths and cost the Australian health system $317 million by 2031 if no further action to tackle the disease is taken.
News & Events
Bupa pledges half a million dollars to end rheumatic heart diseaseResearchers will extend a unique community-led project to end rheumatic heart disease in Aboriginal communities, thanks to nearly half a million dollars in funding from Bupa.
News & Events
RHD a notifiable conditionWestern Australian doctors are now required by law to report all cases of rheumatic heart disease.
Research
Development of Group A streptococcal vaccines: an unmet global health needThis review provides an update on the current status of Group A Streptococcus vaccine development, & describes global efforts to accelerate the development...
Research
Disparity in Mortality From Rheumatic Heart Disease in Indigenous AustraliansThis study was undertaken to provide a comprehensive examination of rheumatic heart disease mortality rates and trends in Indigenous Australians.
Research
Treating trade: the case for clinical engagement with regional trade agreementsThe global burden of non-communicable diseases (NCDs) continues to grow. Although developing settings face fastest growth in incidence, no country is exempt.
Research
The stark reality of rheumatic heart diseaseThis editorial refers to ‘Characteristics, complications, and gaps in evidence-based interventions in rheumatic heart disease: the Global Rheumatic Heart...
Research
The case for global investment in rheumatic heart-disease controlThe review built a case for extending simple and cost–effective measures to all countries. Had these recommendations been put into action, significant...
Research
Group A streptococcal vaccines: Paving a path for accelerated developmentVaccine prevention of GAS infections and their immunological complications has been a goal of researchers for decades.
Research
Progress toward a global Group A streptococcal vaccineThe desire for an effective vaccine arises from the large burden of disease caused by the bacterium, particularly rheumatic fever and rheumatic heart disease.